Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Melanoma 32Neoplasms 19Neoplasm Metastasis 5Brain Neoplasms 3Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid Carcinoma, Anaplastic 1Skin Neoplasms 1Sarcoma 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Multiple Myeloma 1Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1Leukemia, Hairy Cell 1Histiocytosis, Langerhans-Cell 1Hematologic Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Ganglioneuroma 1Ganglioglioma 1Fever 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 4Iodine-131 4Sunitinib 3dabrafenib 2Trastuzumab 2Thyrotropin Alfa 2Thyroidectomy 2Surgical Procedures, Operative 2Gefitinib 2Fluorodeoxyglucose F18 2Bortezomib 2AZD 6244 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1trametinib 1tipifarnib 1tanespimycin 1sargramostim 1romidepsin 1pralsetinib 1pembrolizumab 1pazopanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lenvatinib 1delta 24-sterol reductase 1copanlisib 1cediranib 1aldesleukin 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Thyroid Cancer, Papillary × dabrafenib × Clear all
NCT01723202 2025-08-24

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
53 enrolled 11 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT01534897 2017-03-15

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Massachusetts General Hospital

Phase NA Completed
10 enrolled 9 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Neoplasm Metastasis, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡